NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target

NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore,...

Descripción completa

Detalles Bibliográficos
Autores principales: Lai, Jin-Ping, Rosenberg, Avi Z., Miettinen, Markku M., Lee, Chyi-Chia R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Landes Bioscience 2012
Materias:
Author's View
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518519/
https://www.ncbi.nlm.nih.gov/pubmed/23243610
http://dx.doi.org/10.4161/onci.21059
_version_ 1782252567872405504
author Lai, Jin-Ping
Rosenberg, Avi Z.
Miettinen, Markku M.
Lee, Chyi-Chia R.
author_facet Lai, Jin-Ping
Rosenberg, Avi Z.
Miettinen, Markku M.
Lee, Chyi-Chia R.
author_sort Lai, Jin-Ping
collection PubMed
description NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results have been obtained in clinical trials testing NY-ESO-1-targeted immunotherapy in subsets of melanoma and synovial sarcoma patients.
format Online
Article
Text
id pubmed-3518519
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher Landes Bioscience
record_format MEDLINE/PubMed
spelling pubmed-35185192012-12-14 NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target Lai, Jin-Ping Rosenberg, Avi Z. Miettinen, Markku M. Lee, Chyi-Chia R. Oncoimmunology Author's View NY-ESO-1 (CTAG 1B) is highly expressed in the majority of synovial sarcomas and myxoid/round cell liposarcomas as well as in a subset of melanomas, but only rarely in other mesenchymal tumors. This points to a potential for using NY-ESO-1 in the differential diagnosis of these lesions. Furthermore, promising results have been obtained in clinical trials testing NY-ESO-1-targeted immunotherapy in subsets of melanoma and synovial sarcoma patients. Landes Bioscience 2012-11-01 /pmc/articles/PMC3518519/ /pubmed/23243610 http://dx.doi.org/10.4161/onci.21059 Text en Copyright © 2012 Landes Bioscience http://creativecommons.org/licenses/by-nc/3.0/ This is an open-access article licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. The article may be redistributed, reproduced, and reused for non-commercial purposes, provided the original source is properly cited.
spellingShingle Author's View
Lai, Jin-Ping
Rosenberg, Avi Z.
Miettinen, Markku M.
Lee, Chyi-Chia R.
NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
title NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
title_full NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
title_fullStr NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
title_full_unstemmed NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
title_short NY-ESO-1 expression in sarcomas: A diagnostic marker and immunotherapy target
title_sort ny-eso-1 expression in sarcomas: a diagnostic marker and immunotherapy target
topic Author's View
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3518519/
https://www.ncbi.nlm.nih.gov/pubmed/23243610
http://dx.doi.org/10.4161/onci.21059
work_keys_str_mv AT laijinping nyeso1expressioninsarcomasadiagnosticmarkerandimmunotherapytarget
AT rosenbergaviz nyeso1expressioninsarcomasadiagnosticmarkerandimmunotherapytarget
AT miettinenmarkkum nyeso1expressioninsarcomasadiagnosticmarkerandimmunotherapytarget
AT leechyichiar nyeso1expressioninsarcomasadiagnosticmarkerandimmunotherapytarget

Ejemplares similares